The Medicines Company

NASDAQ: MDCO
$84.90
+$0.00 (+0.0%)
Closing price January 6, 2020

Novartis Finally Comes Through With Its Acquisition of Medicines Co

Medicines Co. (NASDAQ: MDCO) shares shot up on Monday after it was reported that Novartis A.G. (NYSE: NVS) will be acquiring the firm. The transaction was unanimously approved by the ...
Read Full Story »

Top Analyst Upgrades & Downgrades: Deere, Energizer, First Energy, Foot Locker, Lam Research, Lululemon, Netflix, NVIDIA, PG&E, Williams Companies and More

Stocks were indicated to open higher on Monday after the Dow Jones Industrial Average and S&P 500 had pulled back after hitting all-time highs last week. The economic readings keep ...
Read Full Story »

Will Medicines Co Be the Next Target of Novartis?

Medicines Co. (NASDAQ: MDCO) shares shot up on Tuesday after it was reported that Novartis A.G. (NYSE: NVS) might be eyeing this company as its newest acquisition. Currently, Medicines has ...
Read Full Story »

Baird Has 3 Top Biotech Picks With Huge Upcoming Potential Catalysts

Needless to say, the biotech world has had a difficult 2019, with the SPDR S&P Biotech ETF (NYSE: XBI) down 20% from highs posted in April. Even the biggest and ...
Read Full Story »

Why This Late-Stage LDL-Cholesterol Study Could Be a Big Hit

The Medicines Co. (NASDAQ: MDCO) shares made a handy gain on Tuesday after the firm announced results from its late-stage trial in the treatment of low-density lipoprotein cholesterol (LDL-C). Specifically, ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Annaly, Amazon, Enterprise Products, Kinder Morgan, Lululemon, RealReal, Snap, Square, Under Armour and More

Stocks were indicated to open lower on Tuesday after the long weekend on fears about how the new tariffs implemented on September 1 may face pushback from China. The bull ...
Read Full Story »

What This Cholesterol Study Means Going Forward

The Medicines Co. (NASDAQ: MDCO) shares jumped early on Monday after the firm announced results from its late-stage cholesterol study. Specifically, it reported results from its Phase 3 study of ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Amazon, Aurora Cannabis, Cleveland-Cliffs, FedEx, Ferrari, Grubhub, Hexo, Proofpoint, Shutterfly, Starbucks and More

Stocks were indicated to have a small gain ahead of the opening bell on Friday. The S&P 500 has challenged all-time highs and the Nasdaq put in a new high ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Bunge, Carbonite, FedEx, Kinder Morgan, Micron, Monster Beverage, Teva, Western Digital and More

Stocks were indicated to open marginally lower on Thursday morning, and the market has felt a bit directionless of late while it awaits a trade deal with China. Investors need ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Apple, Conoco, Internap, Micron, Steelcase, Vulcan Materials, Wipro and More

Despite Fed Chair Jerome Powell and the FOMC signaling the Federal Reserve is going to be all but out of the rate-hiking business this year and most of next year, ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Arena Pharma, Autodesk, Coca-Cola, GE, Marvell, Monster Beverages, Nabors, Procter & Gamble and More

The futures traded slightly higher Thursday morning as the markets digested yesterday's upside move. Positive talk on trade and some more benign inflation data were seen as the key reasons ...
Read Full Story »

30 Big Biotech Events Coming in 2018

Over the past year, biotech companies have more or less kept pace with the markets, but they have the potential to break out in 2018. While they have been the ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Cognizant Tech, Etsy, GoPro, Illumina, Shake Shack, Travelers and More

Stocks were indicated to open marginally lower after a more or less inline payrolls report from the Labor Department. The Dow was indicated down 21 points and the S&P 500 ...
Read Full Story »

These 5 Biotech Stocks Could Be Big Takeover Targets in 2017

After a very tough year for the biotech stocks last year, they initially jumped after the election of Donald Trump as investors hoped that the rhetoric on drug pricing would ...
Read Full Story »

Insider Buying Volume Big as Trump Rally Rolls On: Transdigm, Medicines Company, Medley Capital, W&T Offshore and More

Another week, another solid performance for stocks, as the rally that started after the presidential election continues. We believe that it is very possible the Trump rally could have legs into ...
Read Full Story »